Form D · Biotechnology
Alphina Therapeutics, Inc.
New Haven, CT · CIK 0001882991
Offering snapshot reported Mar 16, 2026 · SEC filing
- Reported sold
- $154K Offering amount: $10M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 16, 2026 | Initial | $153,715 | No comparison | 3 | SEC filing |
| Sep 15, 2021 | Initial | $16,851,590 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576568
Simple Agreements for Future Equity (SAFEs)
Source: Form D, filed Mar 16, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anurag Agarwal | Director |
| Ranjit Bindra | Director |
| Stanley Choy | Executive |
| Matthew Cohen | Director |
| Colleen Cuffaro | Director |
| Barbara Fox | Director, Executive |
| Nicholas J Galli | Director, Executive |
| Kevin Rakin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
55 Church Street
New Haven, CT, 06510
New Haven, CT, 06510